PATENT CLAIM ANALYSIS

Application Number: 15771941
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "037000"]

Abstract:
This invention concerns the use of mefloquine in relation to  Mycobacterium tuberculosis . This invention also concerns the combination of mefloquine with drugs used in first and second choice treatment of tuberculosis, achieving a reduction in the treatment period of tuberculosis (TB) and the treatment of multi-drug resistant tuberculosis (MDR-TB).

Claim (Index 4):
Use of mefloquine in a fixed dose in combination with at least one, and a maximum of 3, anti-tuberculosis drugs in the preparation of a medicament for the treatment of tuberculosis, where the anti-tuberculosis drugs are selected from the group isoniazid, pyrazinamide, rifampicin, ethambutol, streptomycin, ethionamide, aminosalicylic acid, cycloserine, amikacin, Kanamycin, capreomycin, linezolid, gatifloxacin, moxifloxacin, sparfloxacin, ofloxacin, ciprofloxacin and levofloxacin.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 91.0
- Lexical Diversity: 1.64706
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['10844992', '15546680', '15409911', '14112720', '14816377']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7780835277646734
- 35 USC 102 Novelty (BERT): 0.5086005288163062
- Combined Prediction Score: 0.7511352278698367
- Mean Citation Score: 244.150188
- Max Citation Score: 269.5635
- Similarity Product: 191.6783415087461

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test